Technological advances and proteomic applications in drug discovery and target deconvolution: identification of the pleiotropic effects of statins

Research output: Contribution to journalReview article

Abstract

Proteomic-based techniques provide a powerful tool for identifying the full spectrum of protein targets of a drug, elucidating its mechanism(s) of action, and identifying biomarkers of its efficacy and safety. Herein, we outline the technological advancements in the field, and illustrate the contribution of proteomics to the definition of the pharmacological profile of statins, which represent the cornerstone of the prevention and treatment of cardiovascular diseases (CVDs). Statins act by inhibiting 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase, thus reducing cholesterol biosynthesis and consequently enhancing the clearance of low-density lipoproteins from the blood; however, HMG-CoA reductase inhibition can result in a multitude of additional effects beyond lipid lowering, known as ‘pleiotropic effects’. The case of statins highlights the unique contribution of proteomics to the target profiling of a drug molecule.

Original languageEnglish
Pages (from-to)848-869
Number of pages22
JournalDrug Discovery Today
Volume22
Issue number6
DOIs
Publication statusPublished - Jun 1 2017

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this